Article (Scientific journals)
In vitro evaluation of the anti-apoptotic drug Z-VAD-FMK on human ovarian granulosa cell lines for further use in ovarian tissue transplantation.
Fransolet, Maïté; HENRY, Laurie; LABIED, Soraya et al.
2015In Journal of Assisted Reproduction and Genetics
Peer Reviewed verified by ORBi
 

Files


Full Text
Fransolet M 2015.pdf
Publisher postprint (929.15 kB)
Request a copy

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Ovarian granulosa cells; Z-VAD-FMK; Etoposide; Hypoxia;; Ovarian transplantation; Fertility preservation
Abstract :
[en] PURPOSE: Because ovarian granulosa cells are essential for oocyte survival, we examined three human granulosa cell lines as models to evaluate the ability of the pan-caspase inhibitor benzyloxycarbonyl-Val-Ala-Asp-fluoromethyl ketone (Z-VAD-FMK) to prevent primordial follicle loss after ovarian tissue transplantation. METHODS: To validate the efficacy of Z-VAD-FMK, three human granulosa cell lines (GC1a, HGL5, COV434) were treated for 48 h with etoposide (50 mug/ml) and/or Z-VAD-FMK (50 muM) under normoxic conditions. To mimic the ischemic phase that occurs after ovarian fragment transplantation, cells were cultured without serum under hypoxia (1 % O2) and treated with Z-VAD-FMK. The metabolic activity of the cells was evaluated by WST-1 assay. Cell viability was determined by FACS analyses. The expression of apoptosis-related molecules was assessed by RT-qPCR and Western blot analyses. RESULTS: Our assessment of metabolic activity and FACS analyses in the normoxic experiments indicate that Z-VAD-FMK protects granulosa cells from etoposide-induced cell death. When cells are exposed to hypoxia and serum starvation, their metabolic activity is reduced. However, Z-VAD-FMK does not provide a protective effect. In the hypoxic experiments, the number of viable cells was not modulated, and we did not observe any modifications in the expressions of apoptosis-related molecules (p53, Bax, Bcl-xl, and poly (ADP-ribose) polymerase (PARP)). CONCLUSION: The death of granulosa cell lines was not induced in our ischemic model. Therefore, a protective effect of Z-VAD-FMK in vitro for further use in ovarian tissue transplantation could not be directly confirmed. It will be of interest to potentially use Z-VAD-FMK in vivo in xenograft models.
Disciplines :
Reproductive medicine (gynecology, andrology, obstetrics)
Author, co-author :
Fransolet, Maïté ;  Université de Liège > Département des sciences cliniques > Gynécologie - Obstétrique
HENRY, Laurie  ;  Centre Hospitalier Universitaire de Liège - CHU > Gynécologie-Obstétrique CHR
LABIED, Soraya ;  Centre Hospitalier Universitaire de Liège - CHU > Département de gynécologie-obstétrique > Centre de procréation médicalement assistée (CPMA)
Noël, Agnès ;  Université de Liège > Département des sciences cliniques > Labo de biologie des tumeurs et du développement
Nisolle, Michelle ;  Université de Liège > Département des sciences cliniques > Gynécologie - Obstétrique
Munaut, Carine  ;  Université de Liège > Département des sciences cliniques > Labo de biologie des tumeurs et du développement
Language :
English
Title :
In vitro evaluation of the anti-apoptotic drug Z-VAD-FMK on human ovarian granulosa cell lines for further use in ovarian tissue transplantation.
Publication date :
2015
Journal title :
Journal of Assisted Reproduction and Genetics
ISSN :
1058-0468
eISSN :
1573-7330
Publisher :
Kluwer Academic/Plenum Publishers, New York, United States - New York
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 11 October 2015

Statistics


Number of views
112 (9 by ULiège)
Number of downloads
1 (1 by ULiège)

Scopus citations®
 
10
Scopus citations®
without self-citations
9
OpenCitations
 
9

Bibliography


Similar publications



Contact ORBi